Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
1.
Pediatr Transplant ; 28(1): e14648, 2024 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-38063291

RESUMEN

BACKGROUND: The aim of this study was to assess the impact of serum panel reactive antibodies (PRA) on the outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric thalassemia patients. METHODS: A total of 73 pediatric patients with thalassemia were included in this single-center study. Pre-transplant PRA levels were evaluated, and the patients were divided into two groups: PRA-negative (group 1; n = 44) and PRA-positive (group 2; n = 29). Patient characteristics, including age, gender, donor type, stem cell source, and HLA compatibility, were analyzed. Transplant outcomes, including engraftment, transfusion requirements, and transplant-related complications, were compared between the two groups. Further subgroup analysis was performed based on MFI values. RESULTS: At the time of transplantation, patients in group 1 were younger than those in group 2 (p = .008). The number of fully matched donors within the family (MSD and MFD) was significantly higher in group 1 (p = .049). Additionally, Rh blood group incompatibility was higher in group 2 (p = .03). There was no statistically significant difference in the engraftment days of neutrophils, platelets, and erythrocytes between the two groups. The frequency of poor graft function and graft failure was higher in the group 2, but there was no statistically significant difference. Post-transplant transfusion requirements for platelets and red blood cells were significantly higher in the group 2 (p < .001). Transplant-related complications such as VOD, PRES, and aGvHD were more common in the group 2, but no statistical significance was detected. CONCLUSIONS: Serum PRA in pediatric thalassemia patients may impact the outcomes of HSCT. PRA-positive patients had higher rates of blood product transfusion requirements. Although poor graft function, graft failure, and post-transplant complications were more common in the group 2, statistical significance was not observed. Identifying patients with high PRA levels can assist in optimizing transplant strategies and post-transplant care, leading to improved outcomes for the patients.


Asunto(s)
Enfermedad Injerto contra Huésped , Trasplante de Células Madre Hematopoyéticas , Talasemia , Talasemia beta , Humanos , Niño , Trasplante Homólogo , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Talasemia/terapia , Talasemia beta/terapia , Donantes de Tejidos , Estudios Retrospectivos , Enfermedad Injerto contra Huésped/etiología
2.
Pediatr Transplant ; 28(3): e14758, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38659218

RESUMEN

BACKGROUND: Data on the risk factors and outcomes for pediatric patients with SARS-CoV-2 infection (COVID-19) following hematopoietic stem cell transplantation (HSCT) are limited. OBJECTIVES: The study aimed to analyze the clinical signs, risk factors, and outcomes for ICU admission and mortality in a large pediatric cohort who underwent allogeneic HSCT prior to COVID-19 infection. METHOD: In this nationwide study, we retrospectively reviewed the data of 184 pediatric HSCT recipients who had COVID-19 between March 2020 and August 2022. RESULTS: The median time from HSCT to COVID-19 infection was 209.0 days (IQR, 111.7-340.8; range, 0-3845 days). The most common clinical manifestation was fever (58.7%). While most patients (78.8%) had asymptomatic/mild disease, the disease severity was moderate in 9.2% and severe and critical in 4.4% and 7.6%, respectively. The overall mortality was 10.9% (n: 20). Deaths were attributable to COVID-19 in nine (4.9%) patients. Multivariate analysis revealed that lower respiratory tract disease (LRTD) (OR, 23.20, p: .001) and lymphopenia at diagnosis (OR, 5.21, p: .006) were risk factors for ICU admission and that HSCT from a mismatched donor (OR, 54.04, p: .028), multisystem inflammatory syndrome in children (MIS-C) (OR, 31.07, p: .003), and LRTD (OR, 10.11, p: .035) were associated with a higher risk for COVID-19-related mortality. CONCLUSION: While COVID-19 is mostly asymptomatic or mild in pediatric transplant recipients, it can cause ICU admission in those with LRTD or lymphopenia at diagnosis and may be more fatal in those who are transplanted from a mismatched donor and those who develop MIS-C or LRTD.


Asunto(s)
COVID-19 , Trasplante de Células Madre Hematopoyéticas , Humanos , COVID-19/epidemiología , COVID-19/terapia , COVID-19/mortalidad , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Niño , Masculino , Femenino , Estudios Retrospectivos , Adolescente , Turquía/epidemiología , Preescolar , Factores de Riesgo , SARS-CoV-2 , Lactante , Trasplante Homólogo , Índice de Severidad de la Enfermedad
3.
J Pediatr Hematol Oncol ; 31(10): 760-2, 2009 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-19755923

RESUMEN

Immune hemolytic anemia is a rare condition in childhood. Cold agglutinins have been implicated in the etiology of the hemolysis and frequently observed during Mycoplasma pneumoniae infections. We present here a case of cold agglutinin-related hemolytic anemia, thrombocytopenia, and leukopenia secondary to M. pneumoniae associated pneumonia. It is suggested that even though very rare, M. pneumoniae infection should be considered as the underlying disease in a patient presenting with pancytopenia.


Asunto(s)
Pancitopenia/etiología , Neumonía por Mycoplasma/complicaciones , Anemia Hemolítica Autoinmune/etiología , Niño , Femenino , Humanos , Leucopenia/etiología , Neumonía por Mycoplasma/diagnóstico , Trombocitopenia/etiología
4.
J Pediatr Endocrinol Metab ; 22(2): 187-9, 2009 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-19449677

RESUMEN

Congenital nephrogenic diabetes insipidus (CNDI) is a rare inherited disease characterized by renal tubular unresponsiveness to the antidiuretic effect of arginine-vasopressin due to the mutations of two molecules, the vasopressin V2 receptor (AVPR2) and the aquasporin-2 water channel. We report a novel AVPR2 mutation in a Turkish 18 month-old boy with skeletal anomalies.


Asunto(s)
Diabetes Insípida Nefrogénica/genética , Receptores de Vasopresinas/genética , Cromosomas Humanos X/genética , Análisis Mutacional de ADN , Diabetes Insípida Nefrogénica/congénito , Diabetes Insípida Nefrogénica/diagnóstico , Femenino , Genes Recesivos , Heterocigoto , Humanos , Lactante , Masculino , Madres , Linaje , Radiografía , Escoliosis/congénito , Escoliosis/diagnóstico por imagen , Escoliosis/genética
5.
J Nephrol ; 19(2): 211-4, 2006.
Artículo en Inglés | MEDLINE | ID: mdl-16736423

RESUMEN

Rosai-Dorfman (R-D) disease is a benign lympho-histiocytosis of the lymphoid system. Immune derangement due to cytokine over-expression (tumor necrosis factor (TNF), interleukin (IL)-1b and IL-6) has been considered the cause of R-D disease. We present a 7-year-old boy with R-D disease who developed minimal change nephropathy (MCN) during the progression of R-D disease. The patient was resistant to oral prednisolone; and the remission of both R-D disease and MCN was achieved with oral cyclophosphamide (2 mg/kg, 12 weeks). MCN, the most common cause of nephrotic syndrome in childhood, is generally accepted to emerge by way of cytokine derangement. Correlation between R-D disease activity and the development and remission of nephrotic syndrome in our case suggested that nephrotic syndrome had been induced through some R-D disease-related immune mechanisms.


Asunto(s)
Ciclofosfamida/administración & dosificación , Histiocitosis Sinusal/tratamiento farmacológico , Inmunosupresores/administración & dosificación , Nefrosis Lipoidea/tratamiento farmacológico , Administración Oral , Antiinflamatorios/administración & dosificación , Niño , Citocinas/inmunología , Progresión de la Enfermedad , Resistencia a Medicamentos/efectos de los fármacos , Resistencia a Medicamentos/inmunología , Histiocitosis Sinusal/complicaciones , Histiocitosis Sinusal/inmunología , Histiocitosis Sinusal/patología , Humanos , Masculino , Nefrosis Lipoidea/etiología , Nefrosis Lipoidea/inmunología , Nefrosis Lipoidea/patología , Prednisolona/administración & dosificación
6.
J Clin Neurosci ; 13(1): 109-11, 2006 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-16410207

RESUMEN

Pseudoephedrine is a nasal vasoconstrictor and is contained in many cough and cold medications. It is generally harmless when used in recommended doses. Hypertensive crisis, psychosis, hemorrhagic stroke, and intracranial hemorrhage have been reported as severe complications. We report a 4-year-old girl with nasopharyngeal rhabdomyosarcoma who developed stroke while on pseudoephedrine therapy for 3 days and had no hematological abnormalities.


Asunto(s)
Efedrina/efectos adversos , Accidente Cerebrovascular/inducido químicamente , Preescolar , Femenino , Humanos , Imagen por Resonancia Magnética/métodos , Rabdomiosarcoma/tratamiento farmacológico , Accidente Cerebrovascular/patología , Vasoconstrictores/efectos adversos
7.
Ups J Med Sci ; 115(2): 153-6, 2010 May.
Artículo en Inglés | MEDLINE | ID: mdl-20095924

RESUMEN

Peliosis is a rare benign disorder that is characterized by the presence of diffuse blood-filled cystic spaces and can occur in the liver, spleen, bone-marrow, and lungs. We present a 10-year-old boy with Fanconi anemia who presented with peliosis hepatis due to androgen treatment. Magnetic resonance (MR) imaging revealed multiple non-enhancing masses. Some of the lesions revealed fluid-fluid levels and extrahepatic extension on MR images. Diffusion-weighted (DW) imaging showed restricted diffusion. Fluid-fluid levels and extrahepatic extensions are unusual findings for hepatic peliotic lesions. In addition, DW imaging findings of peliosis hepatis have not been reported previously.


Asunto(s)
Imagen por Resonancia Magnética/métodos , Peliosis Hepática/diagnóstico , Niño , Anemia de Fanconi/complicaciones , Humanos , Masculino , Peliosis Hepática/complicaciones , Peliosis Hepática/patología
8.
Pediatr Nephrol ; 21(5): 733-6, 2006 May.
Artículo en Inglés | MEDLINE | ID: mdl-16491410

RESUMEN

A 5-year-old girl with no underlying immune deficiency or hematologic disease was treated with a combination of ceftriaxone and ampicilline-sulbactam for pneumonia. On the ninth day of the therapy, she developed oliguria, paleness, malaise, immune hemolytic anemia (IHA) and acute renal failure (ARF). Laboratory studies showed the presence of antibodies against ceftriaxone. Acute interstitial nephritis (AIN) was diagnosed by renal biopsy. The patient's renal insufficiency was successfully treated with peritoneal dialysis without any complications. The patient recovered without any treatment using steroids or other immunosuppressive agents.


Asunto(s)
Lesión Renal Aguda/inducido químicamente , Anemia Hemolítica/inducido químicamente , Antibacterianos/efectos adversos , Ceftriaxona/efectos adversos , Nefritis Intersticial/inducido químicamente , Enfermedad Aguda , Lesión Renal Aguda/diagnóstico , Lesión Renal Aguda/inmunología , Lesión Renal Aguda/terapia , Ampicilina/efectos adversos , Anemia Hemolítica/diagnóstico , Anemia Hemolítica/inmunología , Preescolar , Prueba de Coombs , Femenino , Humanos , Inmunoglobulina G/inmunología , Nefritis Intersticial/diagnóstico , Nefritis Intersticial/inmunología , Nefritis Intersticial/terapia , Diálisis Peritoneal , Neumonía/tratamiento farmacológico , Sulbactam/efectos adversos , Resultado del Tratamiento
9.
J Pediatr Hematol Oncol ; 27(1): 37-8, 2005 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-15654276

RESUMEN

Ralstonia pickettii is an aerobic, gram-negative bacterium causing bacteremia following the use of contaminated saline vials, respiratory therapy solutions, skin disinfectants, blood culture mediums, and water supplies. It is rarely associated with human infections. The authors report two cases of R. pickettii bacteremia in patients with Port-A-Caths that could be treated only by removal of the ports.


Asunto(s)
Bacteriemia/etiología , Catéteres de Permanencia/efectos adversos , Catéteres de Permanencia/microbiología , Infecciones por Bacterias Gramnegativas/etiología , Servicio de Oncología en Hospital , Antibacterianos , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Bacteriemia/tratamiento farmacológico , Preescolar , Quimioterapia Combinada/uso terapéutico , Contaminación de Equipos , Femenino , Humanos , Lactante , Infusiones Intravenosas , Neoplasias de Células Germinales y Embrionarias/tratamiento farmacológico , Neoplasias Neuroepiteliales/tratamiento farmacológico , Ralstonia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA